2. Search Result
Search Result
Results for "

GLUT9

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Recombinant Proteins

2

Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-158056
    URAT1/GLUT9-IN-1

    		GLUT URAT1 Metabolic Disease
    URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .
    URAT1/GLUT9-IN-1
  • HY-144305
    KPH2f

    		URAT1 GLUT Infection
    KPH2f is a safe, orally active, and effective dual URAT1/GLUT9 inhibitor with IC50s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively. KPH2f shows little effects on OAT1 and ABCG2 (IC50=32.14 and 26.74 μM) .
    KPH2f
  • HY-172774
    TRPV1 antagonist 10

    		TRP Channel URAT1 GLUT Cytochrome P450 Interleukin Related TNF Receptor Neurological Disease Inflammation/Immunology Endocrinology
    TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC50 = 33.06 nM), moderate to weak URAT1 (IC50 = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain .
    TRPV1 antagonist 10
  • HY-183543
    URAT1/GLUT9-IN-2

    		URAT1 GLUT Metabolic Disease Endocrinology
    URAT1/GLUT9-IN-2 (Compound 42) is a selective, orally active URAT1/GLUT9 inhibitor, with an IC50 of 2.81 μM against URAT1 and an IC50 of 12.53 μM against GLUT9. URAT1/GLUT9-IN-2 reduces serum uric acid levels and protects renal function. URAT1/GLUT9-IN-2 can be used in research related to hyperuricemia and hyperuricemic nephropathy .
    URAT1/GLUT9-IN-2
  • HY-183658
    URAT1/GLUT9-IN-3

    		URAT1 GLUT Metabolic Disease Inflammation/Immunology
    URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC50 values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia .
    URAT1/GLUT9-IN-3
  • HY-162829
    hURAT1 inhibitor 1

    		URAT1 GLUT Metabolic Disease
    hURAT1 inhibitor 1 (compound 27b) is an isomarine-based, orally active dual hURAT1/GLUT9 inhibitor with IC50s of 0.16 μM and 4.47 μM, respectively, and has anti-hyperuricemia effects. hURAT1 inhibitor 1 showed significant uric acid-lowering activity in a hyperuricemia mouse model (10 mg/kg dose). hURAT1 inhibitor 1 had no significant in vitro cytotoxicity or in vivo hepatotoxicity and showed good PK characteristics .
    hURAT1 inhibitor 1
  • HY-182000
    Xanthine oxidase-IN-23

    		Xanthine Oxidase BCRP GLUT Metabolic Disease
    Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia .
    Xanthine oxidase-IN-23
  • HY-RS13175
    SLC2A6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SLC2A6 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC2A6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SLC2A6 Human Pre-designed siRNA Set A
    SLC2A6 Human Pre-designed siRNA Set A
  • HY-RS13177
    SLC2A9 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SLC2A9 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC2A9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SLC2A9 Human Pre-designed siRNA Set A
    SLC2A9 Human Pre-designed siRNA Set A
  • HY-180271
    Xanthine oxidase-IN-21

    		Xanthine Oxidase NF-κB TNF Receptor Interleukin Related URAT1 GLUT Metabolic Disease
    Xanthine oxidase-IN-21, a Genipin (HY-17389) derivative, is an orally active mixed competitive xanthine oxidase (XOD) inhibitor with an IC50 of 0.68 μM. Xanthine oxidase-IN-21 reduces renal fibrosis by decreasing α-SMA expression and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α through NF-κB pathway regulation. Xanthine oxidase-IN-21 also inhibits URAT1 and GLUT9 expression, promoting uric acid excretion and lowering serum uric acid levels. Xanthine oxidase-IN-21 shows significantly hepatorenal protection activity. Xanthine oxidase-IN-21 can be used for the research of hyperuricemia .
    Xanthine oxidase-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: